Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
- Fadini G. P.
- Bottigliengo D.
- D'Angelo F.
- Cavalot F.
- Bossi A. C.
- Zatti G.
- Baldi I.
- Avogaro A.
- Consoli A.
- Formoso G.
- Grossi G.
- Pucci A.
- Sesti G.
- Andreozzi F.
- Capobianco G.
- Gatti A.
- Bonadonna R.
- Zavaroni I.
- Cas A. D.
- Felace G.
- Volsi P. L.
- Buzzetti R.
- Leto G.
- Sorice G. P.
- D'Angelo P.
- Morano S.
- Duratorre E.
- Franzetti I.
- Morpurgo P. S.
- Orsi E.
- Querci F.
- Boemi M.
- Petrelli M.
- Aimaretti G.
- Karamouzis I.
- Saglietti G.
- Cazzetta G.
- Cervone S.
- Devangelio E.
- Lamacchia O.
- Arena S.
- Di Benedetto A.
- Frittitta L.
- Giordano C.
- Piro S.
- Rizzo M.
- Chianetta R.
- Mannina C.
- Anichini R.
- Penno G.
- Solini A.
- Fattor B.
- Bonora E.
- Cigolini M.
- Lapolla A.
- Chilelli N. C.
- Poli M.
- Simioni N.
- Frison V.
- Vinci C.
DOIAbstract
Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter retrospective study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide extended release. The primary endpoint was change from baseline in HbA1c. Secondary endpoints were changes in fasting plasma glucose, body weight, and systolic blood pressure. Automated software extracted data from the same clinical electronic chart system at all centers. Propensity score matching (PSM) was used to generate comparable cohorts to perform outcome analysis. Results: We inc...
Add to ORKG